Cargando…
Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe form. Myeloid-derived suppressive cells (MDSCs) are inhibitory cells that contribu...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835351/ https://www.ncbi.nlm.nih.gov/pubmed/35154077 http://dx.doi.org/10.3389/fimmu.2021.801410 |
_version_ | 1784649411725361152 |
---|---|
author | Jiménez-Cortegana, Carlos Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Álvarez, Nerissa Sousa, Alberto Cantón-Bulnes, Luisa Vilariño-García, Teresa Fuentes, Sandra Martín, Salomón Jiménez, Marta León-Justel, Antonio de la Cruz-Merino, Luis Garnacho-Montero, José Sánchez-Margalet, Víctor |
author_facet | Jiménez-Cortegana, Carlos Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Álvarez, Nerissa Sousa, Alberto Cantón-Bulnes, Luisa Vilariño-García, Teresa Fuentes, Sandra Martín, Salomón Jiménez, Marta León-Justel, Antonio de la Cruz-Merino, Luis Garnacho-Montero, José Sánchez-Margalet, Víctor |
author_sort | Jiménez-Cortegana, Carlos |
collection | PubMed |
description | Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe form. Myeloid-derived suppressive cells (MDSCs) are inhibitory cells that contribute to immunosuppression in patients with cancer and infection. Increased levels of MDSCs have been found in COVID-19 patients, although their role in the pathogenesis of severe COVID-19 has not been clarified. For this reason, we raised the question whether MDSCs could be useful in the follow-up of patients with severe COVID-19 in the intensive care unit (ICU). Thus, we monitored the immunological cells, including MDSCs, in 80 patients admitted into the ICU. After 1, 2, and 3 weeks, we examined for a possible association with mortality (40 patients). Although the basal levels of circulating MDSCs did not discriminate between the two groups of patients, the last measurement before the endpoint (death or ICU discharge) showed that patients discharged alive from the ICU had lower levels of granulocytic MDSCs (G-MDSCs), higher levels of activated lymphocytes, and lower levels of exhausted lymphocytes compared with patients who had a bad evolution (death). In conclusion, a steady increase of G-MDSCs during the follow-up of patients with severe COVID-19 was found in those who eventually died. |
format | Online Article Text |
id | pubmed-8835351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88353512022-02-12 Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19 Jiménez-Cortegana, Carlos Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Álvarez, Nerissa Sousa, Alberto Cantón-Bulnes, Luisa Vilariño-García, Teresa Fuentes, Sandra Martín, Salomón Jiménez, Marta León-Justel, Antonio de la Cruz-Merino, Luis Garnacho-Montero, José Sánchez-Margalet, Víctor Front Immunol Immunology Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe form. Myeloid-derived suppressive cells (MDSCs) are inhibitory cells that contribute to immunosuppression in patients with cancer and infection. Increased levels of MDSCs have been found in COVID-19 patients, although their role in the pathogenesis of severe COVID-19 has not been clarified. For this reason, we raised the question whether MDSCs could be useful in the follow-up of patients with severe COVID-19 in the intensive care unit (ICU). Thus, we monitored the immunological cells, including MDSCs, in 80 patients admitted into the ICU. After 1, 2, and 3 weeks, we examined for a possible association with mortality (40 patients). Although the basal levels of circulating MDSCs did not discriminate between the two groups of patients, the last measurement before the endpoint (death or ICU discharge) showed that patients discharged alive from the ICU had lower levels of granulocytic MDSCs (G-MDSCs), higher levels of activated lymphocytes, and lower levels of exhausted lymphocytes compared with patients who had a bad evolution (death). In conclusion, a steady increase of G-MDSCs during the follow-up of patients with severe COVID-19 was found in those who eventually died. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8835351/ /pubmed/35154077 http://dx.doi.org/10.3389/fimmu.2021.801410 Text en Copyright © 2022 Jiménez-Cortegana, Sánchez-Jiménez, Pérez-Pérez, Álvarez, Sousa, Cantón-Bulnes, Vilariño-García, Fuentes, Martín, Jiménez, León-Justel, de la Cruz-Merino, Garnacho-Montero and Sánchez-Margalet https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Jiménez-Cortegana, Carlos Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Álvarez, Nerissa Sousa, Alberto Cantón-Bulnes, Luisa Vilariño-García, Teresa Fuentes, Sandra Martín, Salomón Jiménez, Marta León-Justel, Antonio de la Cruz-Merino, Luis Garnacho-Montero, José Sánchez-Margalet, Víctor Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19 |
title | Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19 |
title_full | Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19 |
title_fullStr | Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19 |
title_full_unstemmed | Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19 |
title_short | Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19 |
title_sort | low levels of granulocytic myeloid-derived suppressor cells may be a good marker of survival in the follow-up of patients with severe covid-19 |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835351/ https://www.ncbi.nlm.nih.gov/pubmed/35154077 http://dx.doi.org/10.3389/fimmu.2021.801410 |
work_keys_str_mv | AT jimenezcorteganacarlos lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT sanchezjimenezflora lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT perezperezantonio lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT alvareznerissa lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT sousaalberto lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT cantonbulnesluisa lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT vilarinogarciateresa lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT fuentessandra lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT martinsalomon lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT jimenezmarta lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT leonjustelantonio lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT delacruzmerinoluis lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT garnachomonterojose lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 AT sanchezmargaletvictor lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19 |